New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTB-500 vs SLU-PP-332

TB-500 vs SLU-PP-332

Side-by-side comparison of key properties, dosing, and research.

Recovery & Repair
TB-500
Recovery & RepairFat Loss & Metabolic
SLU-PP-332
Summary
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in nearly all human and animal cells. It promotes cell migration to injury sites, accelerates tissue regeneration, and reduces chronic inflammation.
SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
Half-Life
2–3 hours
Not established in humans; rodent pharmacokinetics suggest hours
Admin Route
SubQ, IM
Oral (research), Subcutaneous (research)
Research
Typical Dose
2–2.5 mg
Not established for humans; rodent studies used ~100 mg/kg/day
Frequency
Twice weekly
Once daily in rodent studies
Key Benefits
  • Enhances muscle tissue regeneration
  • Accelerates healing of wounds and injuries
  • Reduces inflammation and pain
  • Improves flexibility and mobility
  • Promotes new blood vessel formation
  • Supports hair growth and skin health
  • May improve cardiac function after injury
  • Systemic healing effect — works at distance from injection site
  • Significant enhancement of aerobic endurance capacity
  • Increases mitochondrial density and oxidative metabolism in muscle
  • Promotes beneficial shift toward oxidative muscle fiber phenotype
  • Improves cardiac efficiency and cardiovascular fitness markers
  • Potential for obesity, metabolic syndrome, and heart failure treatment
  • Exercise mimetic for populations unable to exercise (disability, frailty, disease)
Side Effects
  • Injection site discomfort
  • Fatigue (rare)
  • Headache (rare)
  • Limited human data; all studies are preclinical (rodent)
  • Unknown cardiovascular effects with long-term or high-dose use in humans
  • Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
  • Off-target effects not fully characterized
Stacks With